Mystic Pharmaceuticals is emerging as a leading innovator in patient focused Drug Delivery for Ophthalmic and Intranasal drugs and biologics
ثبت نشده
چکیده
Timothy Sullivan is Co-Founder, President & CEO of Mystic Pharmaceuticals. Over the past 37 years he has created novel technologies, products, and services and grown seven companies, three of which were acquired by major corporations. Mr. Sullivan is co-inventor of Mystic’s novel drug delivery technology platforms and responsible for defining both the technological and strategic direction of Mystic. He has recruited and led a highly accomplished team of scientists, engineers and business professionals through early stage R&D programs, clinical trials and the deployment of a cGMP production facility for Mystic's innovative delivery technologies. He holds ten issued/pending patents in the field of drug/biologic packaging and delivery. About
منابع مشابه
A Review of Vesicular and Polymeric Nano-systems in Olanzapine Drug Delivery
Olanzapine (2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno [2, 3-b][1, 5]benzodiazepine) is an antipsychotic drug with poor water-solubility that has a suitable affinity to some receptors. This benzodiazepine derivative is a new (atypical) antipsychotic drug and has a wide range of efficacy, especially in treatment of patients with negative psychiatric symptoms of schizophrenia. Olanzapine is ...
متن کاملDesign of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate
Objective(s): Ketotifen fumarate (KF) is a selective and noncompetitive histamine antagonist (H1-receptor) that is used topically in the treatment of allergic conditions of rhinitis and conjunctivitis. The aim of this study was to formulate and improve an ophthalmic delivery system of KF.Ocular nanoparticles were prepared with the objective of reducing the frequency of administration and obtain...
متن کاملEmerging patient safety issues under health care reform: follow-on biologics and immunogenicity
US health care reform includes an abbreviated pathway for follow-on biologics, also known as biosimilars, in an effort to speed up access to these complex therapeutics. However, a key patient safety challenge emerges from such an abbreviated pathway: immunogenicity reactions. Yet immunogenicity is notoriously difficult to predict, and even cooperative approaches in licensing between companies h...
متن کاملTheoretical study of interaction between aspirine drug and Al-soped graphene nanostructure toward designing of suitable nanocarrier for drug delivery
Background: In recent years, the unique physical and chemical properties of carbon nanostructures has led to many advancements in various fields, including chemistry and pharmaceuticals. Graphene is one of the carbon nanostructures which have attracted significant attention from researchers in adsorption and release of various drugs. Due to the high surface area of graphene, it can be used as a...
متن کاملFreeze-dried k-carrageenan/chitosan polyelectrolyte complex-based insert: a novel intranasal delivery system for sumatriptan succinate
Intranasal route, ensuring suitable bioavailability of medicines under circumvention of the gastrointestinal degradation and hepatic first-pass elimination, has been a popular choice for drug delivery. Among nasal dosage forms, mucoadhesive solid inserts have been shown to resist mucociliary clearance and provide a prolonged nasal residence time. Hence, the purpose of this study was the prepara...
متن کامل